It is argued that resistance to targeted therapies, endocrine therapies, and PARP inhibitors should not be treated as a problem separate from immunotherapy resistance, but rather, these resistant states often converge on the same three axes that govern immunotherapy resistance (immune visibility, access, and effector f...
Ha-Eun Jeong, Heesun Choi, W. Lim et al.· Journal of Experimental &...· 0 citations
The rapid expansion of the oncology literature has outpaced manual curation of clinically relevant gene-cancer-drug associations and oncogenic driver evidence. Existing automated approaches often lack transparency or are difficult to scale across heterogeneous data sources. To address this gap, we developed megaMine, a...
Muhammad Junaid, K. Prazanowska, Ha-Eun Jeong et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.